期刊文献+

5-氮杂胞苷对结肠癌细胞CHD5基因表达及细胞增殖活性的影响 被引量:3

5-Aza-2'-deoxycytidine inhibits CHD5 gene expression and proliferation of human colon carcinoma cells
下载PDF
导出
摘要 目的研究甲基化转移酶抑制剂5-氮杂-2-脱氧胞苷(5-氮杂胞苷,AZA)对人肿瘤相关基因CHD5(染色质解旋酶DNA结合蛋白5)在结肠癌细胞中的基因转录的诱导作用以及其对细胞增殖的影响。方法 5μmol/L 5-氮杂胞苷分别作用于Lovo和SW480细胞,连续作用72 h后,用荧光定量PCR(qPCR)检测两种结肠癌细胞系中CHD5mRNA的表达,重亚硫酸盐测序(BSP)法分析启动子区的甲基化状况,MTT法分析5-氮杂胞苷对Lovo和SW480细胞增殖的影响。结果 5μmol/L 5-氮杂胞苷处理Lovo和SW480细胞72 h后,Lovo和SW480细胞中CHD5基因的发生了去甲基化,其mRNA重新表达,细胞生长受到抑制。结论 5-氮杂胞苷能够反转CHD5基因的甲基化状态,调控CHD5 mRNA表达,并能有效地抑制结肠癌细胞的增殖。 Objective To study the effect of 5-Aza-2-deoxycytidine (AZA) on re-expression of the hypermethylated and silenced CHD5 ( Chromodomain, helicase, DNA-binding 5 ) gene in human colon carcinoma cells and cell pro- liferation. Methods Lovo and SW480 cells were exposed to 5 μmoL/L AZA for 72 h, and then CHD5 expression was determined by quantitative RT-PCR (qPCR), methylation status of CHD5 genes was determined by bisulfite sequencing PCR ( BSP), and the proliferation of the cells was evaluated by MTF assay. Results After treatment with 5 μmol/L AZA, the promoter region of the CHD5 gene exhibited a demethylation status, and CHD5 mRNA was re-expressed. Meanwhile, the growth of Lovo and SW480 cells were reduced. Conclusions AZA may reverse methylation of CHD5 gene to regulate the expression of CHD5 gene, and effectively inhibit the ceil proliferation of human colon carcinoma cells.
出处 《基础医学与临床》 CSCD 北大核心 2013年第8期976-980,共5页 Basic and Clinical Medicine
基金 广东省自然科学基金(S2011040005521) 国家青年科学基金(81000226) 国家青年科学基金(81100383) 广东省医学科学技术研究基金(A2011360)
关键词 CHD5基因 甲基化 结肠癌细胞 CHD5 gene methylation colon carcinoma
  • 相关文献

参考文献10

  • 1Sharrard RM,Royds JA,Rogers S,et al. Patterns of methy-lation of the c-myc gene in human colorectal cancer progres-sion [J ].Br J Cancer, 1992,65 : 667 -672.
  • 2赵蕊,吕静野,黄海丽,严启滔.CHD5基因RNAi慢病毒载体的构建及其对结直肠癌细胞生物学功能的影响[J].中国生物工程杂志,2012,32(5):7-11. 被引量:2
  • 3刘丽乔,罗达亚,付晶晶,龚慧,万福生.5-Aza-CdR对人结肠癌Caco-2细胞系P16基因甲基化状态及其生物学表型的影响[J].基础医学与临床,2011,31(2):161-165. 被引量:6
  • 4White PS, Thompson PM, Gotoh T, et al. Definition andcharacterization of a region of lp36. 3 consistently deleted inneuroblastoma [ J ] . Oncogene ,2005 ,24 : 2684 - 2694.
  • 5Piaskowski S,Rieske P,Szybka M,et al. GADD45A andEPB41 as tumor suppressor genes in meningioma pathogene-sis [ J ]. Cancer Genet Cytogenet, 2005 ,162 : 63 —67.
  • 6Fujita T, Igarashi J, Okawa ER, et al. CHD5, a tumorsuppressor gene deleted from lp36. 31 in neuroblastomas[J]. J Natl Cancer Inst, 2008,100:940 -949.
  • 7Thompson PM, Gotoh T, Kok, et al. CHD5 , a new mem-ber of the chromodomain gene family, is preferentially ex-pressed in the nervous system [ J ]. Oncogene, 2003,22 :1002-1011.
  • 8Mulero-Navarro S,Esteller M,Chromatin remodeling factorCHD5 is silenced by promoter CpG island hypermethylationin human cancer [ J]. Epigenetics,2008,3:210-215.
  • 9Zhao R, Yan Q, Lv J, et al. CHD5, a tumor suppressorthat is epigenetically silenced in lung cancer [ J ],LungCancer, 2012,76:324 -331.
  • 10Nguyen CT, Weisenberger DJ, Velicescu M. et al. HistoneH3-lysine 9 methylation is associated with aberrant gene si-lencing in cancer cells and is rapidly reversed by 5-Aza-2,-deoxycytidine[ J]. Cancer Res,2002,62:6456 - 6461.

二级参考文献29

  • 1Zhang Z, Huettner PC, Nguyen L, et al. Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer[ J]. Oncogene 2006, 25:5436 - 5445.
  • 2Naqvi RA, Hussain A, Raish M, et al. Specific 5'CpG island methylation signatures of FHIT and P16 genes and their potential diagnostic relevance in Indian breast cancer patients[ J]. DNA Cell Biol, 2008, 27:517 - 525.
  • 3Morita S, Iida S, Kato K, et al. The synergistic effect of 5- Aza-2'-deoxycytidine and 5-fluorouracil on drug-resistant tumors[J]. Oncology, 2006, 71:437 -445.
  • 4Herman JG. Epigenetic changes in cancer and preneoplasia [J]. Cold Spring Harbor Symp Quant Biol, 2005, 70:329 - 333.
  • 5Gronbaek K, Hother C, Jones PA. Epigenetic changes in cancer[ J ]. APMIS: Acta Pathol Microbiol Immunol Scand, 2007, 115 : 1039 - 1059.
  • 6Gopisetty G, Ramachandran K, Singal R. DNA methylation and apoptosis[J]. Mol Immunol, 2006, 43:1729 - 1740.
  • 7Zochbauer-Moller S, Fong KM, Virmani AK, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers [J]. Cancer Res, 2001, 61:249 -255.
  • 8Hirasawa Y, Arai M, Imazekl F, et al. Methylation status of genes upregulated by demethylating agent 5-Aza-2'-de- oxycytidine in hepatocellular carcinoma [ J ]. Oncology, 2006, 71:77 - 85.
  • 9Wozniak RJ, Klimecki WT, Lau SS, et al. 5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation [ J ]. Oncogene, 2007, 26:77-90.
  • 10Benbrahim-Tallaa L, Waterland RA, Dill AL, et al. Tumor suppressor gene inactivation during cadmium-induced malignant transformation of human prostate cells correlates with over expression of de novo DNA methyltransferase [J]. Environ Health Perspect, 2007, 115: 1454 - 1459.

共引文献6

同被引文献19

  • 1李士谔.DNA甲基化、基因表达与肿瘤[J].基础医学与临床,1996,16(5):321-340. 被引量:25
  • 2杨升,卢辉山.Wnt信号通路与消化道肿瘤关系的研究进展[J].世界华人消化杂志,2007,15(27):2880-2884. 被引量:14
  • 3TAKAHASHI R U, MIYAZAKI H, OCHIYA T. The role ofmicroRNAs in the regulation of cancer stem cells [J/OL]. Frontiers in Genetics, 2014,4 : 295. http://www.ncbi.nlm.nih. gov/pubmed/24427168.
  • 4KANT N M, THRASHER A J, ANGELINI G D, et al. Mi- croRNAs as modulators of stem cells and angiogencsis[J/OL]. Stem Cells, 2014, dot: 10. 1002/stein. 1 629. EEpub ahead of print].
  • 5JONES P A, BAYLIN S B. The epigenomics of cancer[J]. Cell, 2007,128(4) :683-692.
  • 6IORIO M V, FERRACIN M, LIU C G, et al. MicroRNA gene expression deregulation in human breast cancer[J]. Canc- er Research, 2005,65(16) :7065-7070.
  • 7LI L S, YUAN L J, LUO J M, et al. MiR-34a inhibits proli- feration and migration of breast cancer through down-regula tion of Bcl-2 and SIRTl[J].Clinical and Experimental Medi- cine, 2013,13(2) =109-117.
  • 8TOI M, OHASHI Y, SEOW A, et al. The breast cancer working group presentation was divided into three sections= the epidemiolo- gy, pathology and treatment of breast cancer[J]. Japanese Journal of Clinical Oncology, 2010,40(1) : i13-i18.
  • 9VOGT M, MUNDING J, GRUNER M, et al. Frequent con- comitant inactivation of miR-34a and miR-34b/c by CpG meth- ylation in colorectal, pancreatic, mammary, ovarian, urothe- lial, and renal cell carcinomas and soft tissue sarcomas[J]. Virchows Archly= an International Journal of Pathology, 2011,458(3), 313-322.
  • 10WONG K Y, YU L, CHIM C S. DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family [J]. Epigenomics, 2011,3(1) 783-92.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部